Evidence item

The reported episode sensitivity is round-specific and defined over a 12-month primary-cancer follow-up window, not absolute sensitivity. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 17654

Source: Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial · locator {} · excerpt hash sha256:975948940c847aef919c718c7946134148980d8f3fc2118f3e2e94b9d0514697

Episode sensitivity, defined as the proportion of participants diagnosed with a primary cancer within the prespecified follow-up window (within 12 months of the corresponding blood collection) who had a positive MCED test result for that screening episode, was 37.2% in the first round, 27.1% in the second round and 26.7% in the third round.